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Abstract
The management of atherosclerotic renal artery stenosis in patients with hypertension or impaired renal function remains a
clinical dilemma. The current general consensus, supported by the results of the Angioplasty and Stenting for Renal
Atherosclerotic Lesions and Cardiovascular Outcomes for Renal Artery Lesions trials, argues strongly against endovascular
intervention in favor of optimal medical management. We discuss the limitations and implications of the contemporary clinical
trials and present our approach and formulate clear recommendations to help with the management of patients with
atherosclerotic narrowing of the renal artery.
Key words: atherosclerosis, chronic renal insufﬁciency, CKD, hypertension, renal artery stenosis

Introduction
Atherosclerotic renal artery stenosis (ARAS) accounts for >90% of
cases of renal artery stenosis [1]. It is most commonly seen
in older patients (>65 years) and is usually associated with
atheromatous disease in other vascular beds. The incidence
and prevalence are hard to estimate given the asymptomatic
nature of the majority of cases. A study in the US Medicare population estimated an incidence of 3.7/1000 patient-years in patients ≥65 years of age [2]. Another population-based study by
Hansen et al. [3] showed a prevalence of 6.8% in elderly patients.
The clinical signiﬁcance of ARAS and its optimal management
have been topics of great controversy. Early studies reported
that renal artery stenosis is a progressive problem that can lead
to resistant hypertension (HTN) and gradual loss of functional
renal mass resulting in chronic kidney disease (CKD) [4–8]. Its
presence has been linked to increased rates of cardiovascular
events and mortality in patients with atherosclerotic cardiovascular disease [9–11]. This triggered an increasing interest in the
treatment of ARAS by surgical or intravascular intervention. In
1996, the number of endovascular stent procedures done in the
USA tables was estimated to be ∼7600. Over the next decade

this number ballooned to ≥35 000 by the year of 2005 [12]. Interventional cardiologists may have contributed to the rapid increase in
renal artery revascularization via convenient renal intervention
during cardiac catheterization. However, enthusiasm for renal
revascularization diminished in the era of statin therapy and
renin–angiotensin system (RAS) blockade, which are believed to
slow the rate of atherosclerosis progression. Major contemporary
clinical trials, such as the Cardiovascular Outcomes for Renal
Artery Lesions (CORAL) [13] and the Angioplasty and Stenting for
Renal Atherosclerotic Lesions (ASTRAL) [14] trials, have failed to
show statistically signiﬁcant beneﬁt of revascularization over optimal medical management in controlling blood pressure (BP) or preserving kidney function. These two trials have inﬂuenced medical
decision making away from vascular intervention. A timeline of the
clinical approaches to atherosclerotic renovascular disease is
shown in Figure 1 and reﬂects the introduction of new technical
and therapeutic advances used in addressing this clinical problem.

The complex relation of ARAS to renal function
It has been long recognized that renal blood ﬂow largely exceeds
tissue metabolic needs. The kidneys receive ∼20% of the cardiac
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output but utilize <10% of the renal perfusion for tissue metabolism [15]. This was demonstrated again recently with the use
of blood oxygen level–dependent (BOLD) magnetic resonance
imaging (MRI), a new technique that allows direct evaluation of
oxygenation at the renal tissue level using the paramagnetic
characteristics of deoxyhemoglobin [16, 17]. Under physiological
conditions and in healthy subjects, BOLD-MRI consistently demonstrates an oxygenation gradient between the cortex and
the deeper medullary areas [18–20]. A 30–40% reduction in single
kidney perfusion in the context of moderate ARAS was associated
with preservation of tissue oxygenation and cortex to deep medulla oxygen gradient in agreement with the high renal perfusion
relative to tissue needs [21]. However, more severe stenosis
(>70%) did overwhelm the kidneys’ adaptive capacity and resulted in overt cortical hypoxia and inﬂammation [22].
The clinical response to intervention in ﬁbromuscular hyperplasia is more predictable and appears to be true to the physiology of the Goldblatt kidney [23]. On the other hand, the
clinical response to intervention in the atherosclerotic lesion is
unpredictable. This speaks to the differences in the underlying
pathophysiology between the two conditions and highlights
the presence of factors other than the reduction in renal blood
perfusion that contribute to tissue injury in ARAS. Mounting evidence supports the presence of an inﬂammatory state in the
post-stenotic kidney that results in parenchymal tissue damage
by means of endothelial injury, increased generation of reactive
oxygen species and oxidative stress [24–26]. Markers of such an
inﬂammatory state can be detected early in the course of ARAS
before any hemodynamic compromise takes place [27]. This
inﬂammation is believed to be secondary to the atherosclerotic
milieu itself [28]. Moreover, reversal of hypoxia by methods of
vascular stenting did not result in down-regulation of renal
vein inﬂammatory biomarkers such as neutrophil gelatinaseassociated lipocalin, monocyte chemoattractant protein-1 and
tumor necrosis factor-α [29].
In summary, renal tissue injury distal to the atherosclerotic
renovascular lesion is likely a multifactorial process that includes

activation of multiple injurious pathways by the atherosclerotic
environment. ARAS may superimpose hypoxic injury upon the
preexisting atherosclerotic tissue injury in case of advanced
and severe stenosis.
With these observations and evidence in mind, the question
of when to intervene in ARAS remains open for debate.

Current clinical approach
The current attitudes toward the management and treatment of
ARAS have shifted sharply toward optimal medical management. This shift was largely driven by the publication of several
randomized clinical trials [13, 14, 30–33] that failed to show superiority of revascularization over optimal medical therapy in
terms of BP control, preservation of renal function or major cardiovascular or renal events. Based on the conclusions of such a
body of evidence, one might think that the question of how to
manage ARAS has been answered. However, each of these trials
had its own limitations and shortcomings that stem from their
recruitment and inclusion criteria and limit their universal
applicability. As summarized in Table 1, it can be seen that the
studied cohorts across the different trials are very similar. All of
the trials excluded patients with advanced kidney disease, malignant or accelerated HTN, history of unstable heart failure (HF) or
recent acute coronary syndrome. The resulting study cohorts
consisted predominantly of patients with normal to moderate
renal dysfunction and hypertension that is best described as
not optimally controlled. This excluded a subset of patients
who were considered to be ‘high risk’ but who exhibited the clinical features traditionally believed to be associated with renovascular disease [19, 34–37]. An example of such a high-risk patient
is illustrated in Case 1, who presents with malignant hypertension and acute kidney injury (AKI) following three decades of
stable BP control with minimal antihypertensive medication
requirements.
The signiﬁcance of ARAS has traditionally been based on estimation of anatomical stenosis obtained by means of renal
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Table 1. Summary of major clinical randomized trials

Study,
number of
patients
EMMA [30],
49

Primary outcome

Angiography, no
hemodynamic
studies

– DBP ≥95 mmHg on at least
three occasions and/or
receiving
antihypertensive
medications.

– Ambulatory BP at
termination of the
study

Angioplasty, no
hemodynamics
studies

DBP ≥95 mmHg on three
occasions despite being on
two antihypertensive
medications

SBP and DBP at 3 and 12
months after
randomization

Stable BP control with BP <140/
90 mmHg for 1 month prior
to randomization

Worsening renal function
deﬁned as ≥20% decrease
in CrCl compared to
baseline

–

DBP >95 mmHg on three
occasions and/or on
antihypertensive medications
Renal artery stenosis ≥75%
without thrombosis or ≥60%
with thrombosis
Stenosis affecting the main renal
artery that had not been
previously dilated
Functional contralateral kidney
without stenosis

–
–
–
–

>75 years old
CrCl <50 mL/min
Malignant HTN
Hx of stroke, pulmonary
edema or MI within 6
months

CrCl: 73 versus
73 mL/min

–

DBP ≥95 mmHg on three
occasions despite being on
two antihypertensive
medications
Rise in sCr of ≥0.2 mg/dL with
ACEI therapy
Unilateral or bilateral ARAS ≥50%

–
–

Age <18 or >75 years
HTN caused by other
condition
Single functioning
kidney
sCr >1.7 mg/dL
Affected kidney <8 cm
Total renal artery
occlusion
AAA requiring surgery
Unstable CAD or HF
Cancer
Pregnancy

CrCl: 67 ± 23 versus
60 ± 24 mL/min

–

CrCl: 45 versus
46 mL/min

CTA, MRA, angiography;
no hemodynamic
testing

–
–

–
–

–
–
–
–
–
–
–
–

CrCl <1.33 mL/s on two
measurements 1 month apart
Unilateral or bilateral stenosis
≥50%
Controlled BP <140/90 mmHg for 1
month prior to randomization

Renal size <8 cm
Renal artery diameter
<4 mm
CrCl <0.25 mL/s
Diabetes mellitus with
proteinuria >3 g/day
Malignant HTN

Table continues

Atherosclerotic renovascular disease

HTN requirement

Exclusion criteria

–
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STAR [33],
140

Method of ARAS
diagnosis

Inclusion criteria

–

DRASTIC
[31],
106

Baseline renal
function,
angioplasty versus
control
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Study,
number of
patients

Inclusion criteria

Exclusion criteria

ASTRAL
[14],
806

Substantial anatomical
atherosclerotic stenosis in at least
one renal artery
Patients’ doctor is uncertain that
patient would deﬁnitely beneﬁt
from revascularization.

CORAL [13],
947

Severe stenosis deﬁned as
– >80% stenosis or 60–80% with
peak systolic gradient of
≥20 mmHg by angiography
– Systolic velocity >300 cm/s by
duplex sonography
– MRA, CTASBP ≥155 mmHg on
two or more antihypertensive
medications or CKD with eGFR
<60 mL/min/1.73 m2

Requirement of surgical
revascularization
Have high likelihood of
requiring
revascularization within
6 months
Nonatheromatous
cardiovascular disease
Previous revascularization
of RAS
Fibromuscular dysplasia
CKD from to other causes
sCr >354 μmol/L
Kidney length <7 cm
Lesion not treatable with a
single stent
Hospitalization for HF in the
last month

Baseline renal
function,
angioplasty versus
control

Method of ARAS
diagnosis

HTN requirement

Primary outcome

eGFR: 40.3 versus
39.8 mL/min/
1.73m2

CTA, MRA, angiography,
renal US; no
hemodynamic studies
reported

No clear deﬁnition of
uncontrolled or refractory
HTN

Change in renal function
measured by the mean
slope of the reciprocal of
the sCr level over time

eGFR: 58 ± 23.4
versus
57.4 ± 21.7 mL/
min/1.73m2

CTA, MRA, angiography,
renal US; duplex study
not done in all patients

SBP ≥155 mmHg on two or
more antihypertension
medications

Major cardiovascular or
renal events

CAD, coronary artery disease; CrCl, creatinine clearance; MI, myocardial infarction; sCr, serum creatinine; US, ultrasound.
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Table 1. Continued

Downloaded from http://ckj.oxfordjournals.org/ at Washington University, Law School Library on December 20, 2016

CLINICAL KIDNEY JOURNAL

Atherosclerotic renovascular disease

Doppler ultrasonography (RDU) or two-dimensional imaging, including angiography, computed tomographic angiography (CTA)
and magnetic resonance angiography (MRA). A luminal crosssection reduction of 50–60% has been considered signiﬁcant
and is required for inclusion in clinical trials [38]. However,
hemodynamic studies using latex rubber showed that a luminal
stenosis of at least 70–80% is necessary to induce a reduction in
blood ﬂow and renal perfusion [39]. Activation of the RAS and
renin release are believed to be markers of hemodynamic signiﬁcance and major players in renovascular hypertension [40]. Gradual luminal occlusion by balloon inﬂation in human subjects did
not result in renin release until the pressure distal to the stenosis
dropped by ∼10%, correlating with a distal:aortic pressure ratio
(Pd:Pa) of <0.9 and a luminal occlusion of 70–80% [41]. When comparing angiographic parameters to the Pd:Pa ratio, a luminal
stenosis cutoff of >50% was associated with false positive results
in 38% of the cases [42]. Furthermore, the current imaging methods are likely to overestimate the actual severity of luminal stenosis. Angiography, which continues to be considered the gold
standard for estimating luminal stenosis and a key inclusion

criteria in most clinical trials, is far from optimal. Atherosclerotic
disease is more often diffuse, with multiple areas of stenosis or
post-stenotic dilation, which may affect the accuracy of luminal
reduction estimation due to the lack of a good reference segment.
Angiography is also vulnerable to interobserver variability and
performer bias. In the STAR trial, 12 of the 64 patients assigned
to the percutaneous transluminal renal angioplasty (PTRA) arm
did not receive the allocated treatment at the time of the procedure, as the stenosis was found to be <50% [33], and in the CORAL
roll-in period, stenosis was decreased by core laboratory from an
average of 72.5% to 67.3% [43]. On the other hand, the ASTRAL
trial did not have a core laboratory conﬁrmation of angiographic
imaging. All of this highlights the tendency of the criteria used by
modern clinical trials to overestimate the signiﬁcance and severity of ARAS in the studied cohort.
It is important to recognize that the mere presence of an anatomical lesion does not necessarily translate into hemodynamic
signiﬁcance, nor does a certain degree of stenosis exert the same
effect on different patients. When comparing patients with severe renal artery stenosis as evident by increased hypoxia signal
on BOLD-MRI to patients with moderate renal artery stenosis and
no evidence of increased hypoxia signal, the degree of renal artery stenosis assessed by CTA scan was not statistically signiﬁcant between the two groups [22]. This speaks to the inability of
two-dimensional imaging used by most clinical trials to accurately evaluate the hemodynamic signiﬁcance of a renal artery
stenotic lesion, as it does not provide any insight regarding
renal ﬂow, translesional pressure gradient or tissue oxygenation.
Parameters obtained noninvasively by renal duplex sonography
have been proposed to better predict the hemodynamic effect
of a lesion. Peak systolic velocity (PSV) has been reported to
have the highest sensitivity (85%) and speciﬁcity (92%) among
other parameters in evaluating renal artery stenosis [44]. Multiple cutoffs ranging from 180 to 300 cm/s have been proposed
by different studies for the diagnosis of a stenosis of ≥70% [45–
49]. A PSV > 300 cm/s was used in the CORAL trials. However,
these suggested values still may be overestimating the severity
of stenosis. Evidence of cortical and medullary hypoxia by
BOLD-MRI was seen with a PSV >384 cm/s [22] and a PSV
>320 cm/s correlated best with a Pd:Pa ratio of <0.9 [42].
In summary, the currently available clinical trials have some
limitations in their abilities to screen and adequately identify severe and hemodynamically signiﬁcant stenosis. Additionally,
these trials have excluded patients with the highest likelihood
of having clinically signiﬁcant disease. This greatly restricts
their applicability to low-risk cohorts with stable or slowly progressive renal failure and amenable to control of hypertension.

When is it reasonable to intervene in ARAS?
The key for the management of ARAS lies in establishing the
functional signiﬁcance of the stenosis, that is, when the ARAS
is actually responsible for activation of the RAS or induces renal
tissue ischemia that is still amenable for reversal by reperfusion
techniques. The ongoing uncertainty regarding the beneﬁt of revascularization reinforces that this is not an easy task. We believe
that two essential criteria must be met for consideration of intervention with endovascular stenting. The ﬁrst is a clinical criterion, that is, a clinical presentation that can result from ARAS
such that it produces an acute to subacute change in BP control
or rate of chronic kidney disease progression. The second is demonstration of a functional lesion. Renal Doppler ultrasonography
is probably the best noninvasive method for such evaluation.
Below we outline some of the clinical scenarios that we believe

Downloaded from http://ckj.oxfordjournals.org/ at Washington University, Law School Library on December 20, 2016

Case 1: A 74-year-old female with stage 3 chronic kidney disease, baseline creatinine (Cr) 1.7 mg/dL [estimated glomerular ﬁltration rate (eGFR) 39 mL/min],
well-controlled hypertension for three decades on a
stable dose of triamterene-hydrochlorothiazide 75–
50 mg daily, hyperlipidemia and gout. Patient presented to the emergency room with acute onset
orthopnea and resting dyspnea. She was found to be
severely hypertensive with BP of 240/144 mmHg.
Other vital signs showed O2 saturation of 96% on
room air, heart rate of 98 bpm and temperature of
36.1°C. Initial lab values showed an elevated Cr of
3.10 mg/dL, blood urea nitrogen (BUN) 46 mg/dL, Na
145 mmol/L K 3.9 mmol/L, and HCO3 20 mmol/L. CBC
showed a WBC of 5 × 109/L, hemoglobin of 79 g/L and
platelets of 132 × 109/L. Urinalysis showed trace protein. FEurea was 11.6%. She was treated with nitroglycerine drip and oral labetalol, Lasix and hydralazine
with gradual improvement in BP. Cr increased to
9.49 mg/dL in the next 48 h with ongoing oliguria and
respiratory distress resulting in hemodialysis initiation. Renal ultrasound showed the right kidney measuring 12.5 cm and the left kidney measuring 10.5 cm.
Renal Doppler showed peaked systolic velocity (PSV)
of 304 cm/s in the right renal artery, 133 cm/s in left
renal artery and 142 cm/s in the aorta. Patient underwent diagnostic and therapeutic angiography that
showed complete occlusion of the right renal artery
that was successfully stented. Following the procedure,
patient’s urine output increased to 3700 mL over the
next 24 h with a decrease in serum Cr and improvement in BP control. She did not require any further
hemodialysis. Cr improved to a nadir of 2.5 mg/dL
and she required only amlodipine 10 mg for BP control.
Almost 5 years later, the patient remains dialysis independent with patent right renal artery stent on followup renal Doppler studies. However, her underlying kidney disease continued to progress and she has reached
stage 5 kidney disease with Cr of 4.32 mg/dL and eGFR
of 12 mL/min/1.73m2.
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Table 2.
Pretest
probability
Low risk
Moderate
risk

High risk

Recommended approach

Recommended imaging

Stable renal function and good
control of BP
(a) Hard to control BP
(b) Acute or subacute worsening
in renal function

Conservative management

No screening

(a) Assess medication and diet compliance.
Conﬁrm poor control of hypertension (24-h
ambulatory BP measurement)
(b) Evaluate for other possible etiologies for renal
dysfunction including glomerulopathy,
nephrotoxins and others

Renal duplex ultrasonography

(a) Resistant, accelerated or
malignant hypertension
(b) Unexplained acute or subacute
deterioration of renal function
(c) Recurrent ﬂash pulmonary
edema in the context of
patient compliance

(a) Obtain imaging studies
(b) Weight beneﬁts versus risks of interventions
(c) Consider intervention in patient with both clinical
symptoms and imaging ﬁndings suggestive of
signiﬁcant lesion

Renal duplex ultrasonography
(a) If negative and strong
clinical suspicion, get CTA
or MRA
(b) If positive, proceed to
angiography and stenting if
signiﬁcant lesion presents

warrant consideration of intravascular intervention and discuss
the evidence with and against such an approach. Table 2 summarizes our clinical approach to patients with ARAS.

Clinical scenarios to raise suspicion of ARAS
Malignant hypertension on the background of previously
well controlled BP
Unexplained malignant or accelerated hypertension with or
without acute renal failure in patients with a previous history
of stable BP control should raise suspicion of acute severe renal
ischemia, such as in the case of renal artery dissection or plaque
rupture. In such patients, an urgent evaluation of renal blood
ﬂow is crucial. This can be initiated with noninvasive techniques
such as renal Doppler study. If ARAS is present, endovascular revascularization should be attempted in patients who are considered reasonable candidates. In Case 1 we present a patient with a
similar presentation where intravascular intervention resulted in
prompt and sustained beneﬁt in both BP control and renal recovery. No clinical trial has directly evaluated the efﬁcacy of revascularization versus conservative medical therapy in such a
condition, but clinical experience and case reports support
such an approach [50, 51]. A recent retrospective study comparing medical management to revascularization in patients who
presented with both accelerated or malignant hypertension
and rapid loss of kidney function reported a signiﬁcant reduction
in risk for death {hazard ratio [HR] 0.12 [95% conﬁdence interval
(CI) 0.02–0.77], P = 0.03} and cardiovascular events [HR 0.28 (95%
CI 0.10–0.60), P < 0.001] [52] with revascularization [52].

intervention should be considered after carefully weighing the
beneﬁts and risks, taking into account the patient’s comorbidities and the likelihood of improving his/her lifestyle. Clinical evidence to support intervention in case of ARAS and resistant
hypertension are controversial. The CORAL and ASTRAL trials
did not support the beneﬁt of revascularization in improving BP
control. However, these studies did not focus on patients with resistant hypertension, deﬁned as BP >140/90 mmHg despite being
on the maximal tolerated dose of three antihypertensive medications, including a diuretic. In the HERCULES trial [53], 99 and 71%
of the patients had uncontrolled BP despite being on two or more
and three or more antihypertensive agents, respectively. Angioplasty with stenting in this study resulted in a signiﬁcant reduction in BP despite a stable number of antihypertensive
medications. The largest mean systolic BP (SBP) reduction of 46
mmHg was seen in patients with a preoperative SBP >180
mmHg. There was no change in renal function at the end of the
36-month follow-up period. This contrasts with the result of a
single-center retrospective study [52] that compared percutaneous transluminal renal angioplasty (PTRA) to medical therapy
in 158 patients with refractory hypertension in which 47 (30%)
underwent revascularization. No difference in terms of BP reduction, death, cardiovascular disease or progression to end-stage
renal disease was noted between the two groups. However, neither study included hemodynamics assessments. A documentation of high PSV with RDU or a Pd:Pa <0.9 may better indicate
clinical signiﬁcance and support the need for vascular
intervention.

Recent increase in antihypertensive requirement in
patients with previously stable BP control

Rapid deterioration of renal function (>30% reduction in
eGFR over ≤3 months) in patients with previously stable
or slowly progressive renal disease

In the absence of a clear explanation for acute worsening of BP
control, such as medication or dietary noncompliance, worsening renal failure, or medication interaction, it is reasonable to
evaluate for ARAS by noninvasive methods such as RDU. However, in situations where adequate BP control is still amenable
with medication adjustment, conservative medical management
with close monitoring of renal function and BP control is preferred. If hypertension becomes resistant, intravascular

While trials evaluating the efﬁcacy of revascularization in preserving or improving renal function failed to show positive results, studies looking particularly at the subset of patients with
recent rapid reduction in renal function have demonstrated
some efﬁcacy after revascularization [54–56]. Also, multiple
small trials and case series have demonstrated recovery of
renal function after a revascularization procedure even in patients with dialysis-dependent end-stage renal disease [57, 58].
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Recurrent ﬂash pulmonary edema (Pickering syndrome)
in the setting of bilateral ARAS
Pickering syndrome was ﬁrst described by in 1988 [60] in a series
of 11 hypertensive patients with recurrent episodes of ﬂash

Case 2: A 84-year-old female with past medical history
of left nephrectomy at age 53 years, stage 4 chronic kidney disease with creatinine (Cr) of 1.4–1.6 mg/dL (eGFR
27 mL/min/1.73 m2), and hypertension well controlled
with a single agent. One month prior to her presentation to our facility, the patient developed progressive
weakness, lack of appetite and lower extremity swelling. She initially presented to an outside hospital 2
weeks after the onset of symptoms and was found to
have a BP of 210/90 mmHg and acute renal failure.
Labs showed Cr of 6.5 mg/dL, blood urea nitrogen
(BUN) 127 mg/dL, Na 132 mmol/L and K 7.0 mmol/L.
Hemodialysis was initiated with improvement in BP
and symptoms. No further evaluation of her acuteon-chronic renal failure was performed and she was
set up for outpatient hemodialysis. The patient presented to our institution 1 week later for a second opinion after having already received four outpatient
hemodialysis treatments. Her vital signs were BP 143/
76 mmHg, heart rate 80 bpm, SaPO2 96% on 2 L oxygen
via nasal cannula and temperature 36.7°C. Laboratory
studies revealed WBC 16 × 109/L, hemoglobin 119 g/L,
platelets 273 × 109/L, Na 127 mmol/L, K 4.7 mmol/L, Cl
−92 mmol/L, HCO3 24 mmol/L, BUN 36 mg/dL, and Cr
3.6 mg/dL. Renal ultrasound showed absent left kidney,
right kidney measuring 8.3 cm with normal echogenicity and no hydronephrosis. Doppler study demonstrated a peak systolic velocity of 481 cm/s at the
origin of the right renal artery and 163 cm/s at the
aorta, consistent with severe ostial stenosis of the
renal artery. Patient underwent renal angiography
with limited contrast exposure that revealed 95% stenosis at the ostium of the right renal artery. Angioplasty
and placement of a drug-eluting stent was performed.
Within the next 24 h the patient made >3 L of urine. Cr
decreased to 2.3 mg/dL on the day of discharge. Eleven
months following discharge, the patient continues to
be dialysis independent with Cr of 2–2.3 mg/dL (eGFR
18 mL/min/1.73 m2) with good control of BP with two
antihypertensive agents.

pulmonary edema (FPE) and evidence of bilateral ARAS. The
pathophysiology of this condition has been well described and
delineated [61] in which the bilateral nature of ARAS prevents
pressure natriuresis and leads to volume expansion. Multiple
studies [62–65] have reported excellent response ranging from
77 to 100% in terms of FPE recurrence and BP control with either
surgical or percutaneous revascularization. None of these studies
was a randomized controlled trial. However, a matched cohortcontrolled study done by Kane et al. [66] compared 50 patients
with HF and ARAS who underwent percutaneous transluminal
renal angioplasty (PTRA) with 1:1 age-matched patients with HF
and ARAS who were treated medically. PTRA resulted in better
control of HF symptoms as evidenced by lower average
New York Heart Association functional class, fewer HF-related
hospitalizations, higher utilization of angiotensin-converting enzyme inhibitors and better control of BP. However, there was no
difference in terms of all-cause mortality.

Conclusion
The results of the ASTRAL and CORAL trials have answered part
of the question of when to intervene in the case of ARAS. These
trials have shown that in patients with stable kidney function
and adequate BP control, the mere presence of renal artery stenosis does not require intervention. On the other hand, clinical
evidence for the beneﬁt or lack of beneﬁt in patients with the
high-risk clinical presentations described above is lacking. A
large, well-designed, randomized clinical trial targeted towards
a such population is still needed. In the meanwhile, we believe
that the conclusion of these contemporary clinical trials should
not be generalized to all patients with ARAS. The beneﬁt of invasive intervention should be weighed against the risks in each patient individually.
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other glomerulopathy warrants consideration of hemodynamic
etiology. Evaluation should be initiated with noninvasive studies
such as RDU. In patients with evidence suggestive of functionally
signiﬁcant stenosis per PSV and/or renal:aortic ratio, endovascular stenting should be considered following careful assessment of
the patient’s overall condition and comorbidities. Case 2 clearly
illustrates such an approach.
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